Text Size

Duke Conte Center for the Neuroscience of Depression in Late Life

This study has been completed.
Sponsor:
Collaborator:
University of Mississippi Medical Center
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00576875
First received: December 18, 2007
Last updated: February 20, 2012
Last verified: February 2012
History of Changes
  Purpose

The proposed Silvio O. Conte Center for Neuroscience of Depression will focus on understanding the neurobiological mechanism of depression. A total of 5 projects are proposed. The center is focused on a single hypothesis. The first project examines localization of lesions, structural changes in critical regions subserving the circuit, alterations in the white matter tracts relevant to the circuit and changes in glutamate. The second project uses post mortem cell counting and cellular localization in serotonin receptors and assessment of the type of cell loss in the orbitofrontal cortex. The third project uses cognitive paradigms and functional MRI to probe the circuit and the role of brain lesions and serotonin on the functioning of this circuit. The fourth project uses transgenic and knockout mice to examine to role of norepinephrine and serotonin as it relates to the circuit. The final project is designed to assess in these transgenic mice using multielectrode array of single neuron recordings of the firing pattern of the circuit neurons in various states and tasks and the role of monoamines in modulating this circuit.


Condition
Major Depression

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Conte Centers for the Neuroscience of Depression

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by Duke University:

Primary Outcome Measures:
  • Each of the projects in the Duke Conte Center has its own aims and primary outcomes [ Time Frame: Up to five years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood for DNA; Post-mortem brain tissue


Enrollment: 795
Study Start Date: August 2006
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Depressed
Older individuals with major depression
Non-depressed
Older individuals without major depression

Detailed Description:

Three shared resources, administrative, research and assessment and data management/statistics are proposed to facilitate the conduct of these projects and to ensure integration at the conceptual, analytical and resource availability level, and flow to the various projects. Findings from the center should greatly enhance our understanding of the biology of depressive disorders and help improve the treatment of these disorders. In addition, the technological innovations developed in the context of this project are likely to be of major importance and relevant to other studies of brain function.

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic; Outpatient psychiatry clinic; Inpatient psychiatry clinic; Self-referral

Criteria

Inclusion Criteria:

For depressed group:

  1. Age > 60 years
  2. Major depression, single episode or recurrent
  3. Ability to read and write English
  4. MMSE >25
  5. Willingness to participate in the follow-up study for at least two years.

For non-depressed group:

  1. Age > 60 years
  2. Ability to read and write English
  3. MMSE >25
  4. Willingness to participate in the follow-up study for at least two years

Exclusion Criteria:

  1. Lifetime alcohol or drug dependence
  2. Conditions associated with MRI abnormalities such hydrocephalus, benign and cancerous brain tumors, epilepsy, Parkinson's disease, Huntington's chorea, dementia, demyelinating diseases, etc.
  3. Endocrine disorder (other than diabetes mellitus)
  4. Any physical or intellectual disability that may affect completion of self rating instruments
  5. Established clinical diagnosis of dementia
  6. Other primary psychiatric disorders, including panic disorder, social phobia, OCD, non-affective psychosis (including schizo-affective disorder), schizophrenia, bipolar disorder
  7. Any metal or pacemaker in the body which precludes MRI.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00576875

Locations
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
University of Mississippi Medical Center
Investigators
Principal Investigator: Ranga R Krishnan, MB, ChB Duke University
  More Information

Additional Information:
Conte Center website  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00576875     History of Changes
Other Study ID Numbers: Pro00007678
Study First Received: December 18, 2007
Last Updated: February 20, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
Depression
Elderly
Neuroimaging
Postmortem
Knockout mouse

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
 Behavioral Symptoms
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on June 18, 2013